A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06)

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(29 sites)

China

The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui

Peking University Third Hospital, Beijing, Beijing Municipality

West China Hospital of Sichuan University, Chengdu, Chengdu

The First Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing Municipality

Chongqing University Cancer Hospital, Chongqing, Chongqing Municipality